Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trial

OBJECTIVE: Because clozapine and risperidone have been shown to reduce neuroinflammation in humans and mice, the Clozapine and Risperidone in Progressive Multiple Sclerosis (CRISP) trial was conducted to determine whether clozapine and risperidone are suitable for progressive multiple sclerosis (pMS...

Descripción completa

Detalles Bibliográficos
Autores principales: La Flamme, Anne C, Abernethy, David, Sim, Dalice, Goode, Liz, Lockhart, Michelle, Bourke, David, Milner, Imogen, Garrill, Toni-Marie, Joshi, Purwa, Watson, Eloise, Smyth, Duncan, Lance, Sean, Connor, Bronwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903182/
https://www.ncbi.nlm.nih.gov/pubmed/33681788
http://dx.doi.org/10.1136/bmjno-2020-000060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903182/
https://www.ncbi.nlm.nih.gov/pubmed/33681788
http://dx.doi.org/10.1136/bmjno-2020-000060

Ejemplares similares